Details of the Drug-Related molecule(s) Interaction Atlas
General Information of Drug (ID: DMNOBFQ)
Drug Name | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Arluy; Mebeverina; Mebeverinum; Arluy (TN); Mebeverina [INN-Spanish]; Mebeverine (INN); Mebeverine [INN:BAN]; Mebeverinum [INN-Latin]; Mebeverine (USAN)(*hydrochloride*); Veratric acid, 4-[ethyl(p-me; Veratric acid, 4-((ethyl(p-methoxy-alpha-methylphenethyl))amino)butyl ester; Veratric acid, 4-((ethyl(p-methoxy-.alpha.-methylphenethyl))amino)butyl ester; Benzoic acid, 3,4-dimethoxy-, 4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl ester; Benzoic acid, 3,4-dimethoxy-, {4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl} ester; Benzoic acid, 3,4-dimethoxy-, 4-(ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl ester; 4-(Ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl 3,4-dimethoxybenzoate;4-(ethyl-(4-methoxy-alpha-methylphenethyl)aminobutyl) veratrate; 4-(ethyl{1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)butyl 3,4-bis(methyloxy)benzoate; 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl 3,4-dimethoxybenzoate
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecule-Related Drug Atlas
Molecule-Related Drug Atlas
Molecule Type:
DTT DOT Drug Status:
Approved Drug(s) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug(s) Targeting Muscarinic acetylcholine receptor M5 (CHRM5)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Molecular Interaction Atlas | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
Drug Off-Target (DOT) |
|
||||||||||||||||||||||||||
References